


60° Congresso della Società Italiana di Gerontologia e Geriatria

Palestra Cognitiva: Brain Training ed Attività Fisica

Nicola Ferrara, MD Dipartimento di Scienze Mediche Traslazionali Università degli Studi di Napoli «Federico II» Presidente della Società Italiana di Gerontologia e Geriatria

Marcus Tullius Cicero (106-65 BC): "It is exercise alone that supports the spirits, and keeps the mind in vigor"




John Adams (1760-1829): "Exercise invigorates, and enlivens all the faculties of body and of mind . . . It spreads a gladness and satisfaction over our minds and qualifies us for every sort of business, and every sort of pleasure"




"Le vecchie menti sono come i vecchi cavalli; le devi tenere in esercizio se vuoi che siano sempre pronte a lavorare."

Mark Twain (1835-1910): "I take my only exercise acting as Pallbearer at the funerals of my friends who exercise

regularly"




Henry Ford (1863-1947): "Exercise is bunk. If you are healthy, you don't need it, and if you are sick, you shouldn't take it"



DIMENSIONE DEL PROBLEMA

The 22 leading diagnoses for direct health expenditures, United States, 2010 (in billions of dollars).



Alan S. Go et al. Circulation. 2014;129:e28-e292



Table 2 Characteristics of the population selected to study the relationship between blood pressure and cognitive impairment (n = 1106) stratified by age

		Age range (years)								
Variables	65-74	75-84	≥ 85							
	(n = 717)	(n = 312)	(n = 77)							
Number of women (%) Educational level Percentage with MMSE	384 (53.5) 3.6 ± 1.4	174 (55.8) 3.1 ± 1.5*	56 (72.4) 3.0 ± 1.6 [†]							
< 24	19.2	24.5*	34.4 [‡]							
GDS score	9.8 ± 6.3	12.2 ± 6.0*	13.1 ± 6.4 [†]							
SBP (mmHg)	143.8 ± 18.4	147.1 ± 19.3*	148.3 ± 20.9 [†]							
DBP (mmHg)	82.3 ± 9.1	81.5 ± 9.2	81.7 ± 8.8							

Table 2 Characteristics of the population selected to study the relationship between blood pressure and cognitive impairment (n = 1106) stratified by age

		Age range (years)							
Variables	65-74	75-84	≥ 85						
	(n = 717)	(n = 312)	(n = 77)						
Number of women (%) Educational level Percentage with MMSE	384 (53.5) 3.6 ± 1.4	174 (55.8) 3.1 ± 1.5*	56 (72.4) 3.0 ± 1.6 [†]						
< 24	19.2	24.5*	34.4 [‡]						
GDS score	9.8 ± 6.3	12.2 ± 6.0*	13.1 ± 6.4 [†]						
SBP (mmHg)	143.8 ± 18.4	147.1 ± 19.3*	148.3 ± 20.9 [†]						
DBP (mmHg)	82.3 ± 9.1	81.5 ± 9.2	81.7 ± 8.8						

Table 2 Characteristics of the population selected to study the relationship between blood pressure and cognitive impairment (n = 1106) stratified by age

		Age range (years)							
Variables	65-74	75-84	≥ 85						
	(n = 717)	(n = 312)	(n = 77)						
Number of women (%) Educational level Percentage with MMSE	384 (53.5) 3.6 ± 1.4	174 (55.8) 3.1 ± 1.5*	56 (72.4) 3.0 ± 1.6 [†]						
< 24	19.2	24.5°	34.4^{\ddagger} $13.1 \pm 6.4^{\dagger}$ $148.3 \pm 20.9^{\dagger}$ 81.7 ± 8.8						
GDS score	9.8 ± 6.3	12.2 ± 6.0*							
SBP (mmHg)	143.8 ± 18.4	147.1 ± 19.3*							
DBP (mmHg)	82.3 ± 9.1	81.5 ± 9.2							

Table 2 Characteristics of the population selected to study the relationship between blood pressure and cognitive impairment (n = 1106) stratified by age

		Age range (years)							
Variables	65-74	75-84	≥ 85						
	(n = 717)	(n = 312)	(n = 77)						
Number of women (%) Educational level Percentage with MMSE	384 (53.5) 3.6 ± 1.4	174 (55.8) 3.1 ± 1.5*	56 (72.4) 3.0 ± 1.6 [†]						
< 24	19.2	24.5°	34.4						
GDS score	9.8 ± 6.3	12.2 ± 6.0*	13.1 ± 6.4 [†]						
SBP (mmHg)	143.8 ± 18.4	147.1 ± 19.3*	148.3 ± 20.9 [†]						
DBP (mmHg)	82.3 ± 9.1	81.5 ± 9.2	81.7 ± 8.8						

Table 3. Prevalence and number of subjects with cognitive impairment without dementia, using different definitions, by age class and gender

					Age	(years)			
Diagnosis		5-69	70	70-74		75-79		80-84		
	N.	%	N.	%	N.	%	N.	%	N.	%
Men										
AACD	31	7.1	39	9.5	46	11.2	40	12.9	156	10.0
AACD-3*	72	16.6	75	18.3	83	20.1	57	18.4	287	18.3
ND-N**	89	20.5	62	15.2	72	17.5	41	13.3	264	16.9
SCC-NI***	9	2.1	5	1.2	10	2.4	5	1.6	29	1.9
Women										
AACD	23	5.7	29	8.0	38	10.3	28	9.9	118	8.3
AACD-3*	58	14.4	70	19.2	87	23.6	59	20.8	274	19.3
ND-N**	80	19.9	65	17.9	54	14.6	45	15.8	244	17.2
SCC-NI***	3	0.7	5	1.4	5	1.4	2	0.7	15	1.1

^{*}Individuals with cognitive impairment without dementia fulfilling only 3 of the 5 AACD criteria.

^{**}Individuals with documented neuropsychological deficits but otherwise with normal cognitive function.

^{***}Individuals with subjective cognitive complaints without neuropsychological impairments.

Table 3. Prevalence and number of subjects with cognitive impairment without dementia, using different definitions, by age class and gender

					Age	(years)			
Diagnosis		5-69	70	-74	75-79		80-84		Total	
	N.	%	N.	%	N.	%	N.	%	N.	%
Men										
AACD	31	7.1	39	9.5	46	11.2	40	12.9	156	10.0
AACD-3*	72	16.6	75	18.3	83	20.1	57	18.4	287	18.3
ND-N**	89	20.5	62	15.2	72	17.5	41	13.3	264	16.9
SCC-NI***	9	2.1	5	1.2	10	2.4	5	1.6	29	1.9
Women										
AACD	23	5.7	29	8.0	38	10.3	28	9.9	118	8.3
AACD-3*	58	14.4		19.2	87	23.6	59	20.8	274	19.3
ND-N**	80	19.9	65	17.9	54	14.6	45	15.8	244	17.2
SCC-NI***	3	0.7	5	1.4	5	1.4	2	0.7	15	1.1

^{*}Individuals with cognitive impairment without dementia fulfilling only 3 of the 5 AACD criteria.

^{**}Individuals with documented neuropsychological deficits but otherwise with normal cognitive function.

^{***}Individuals with subjective cognitive complaints without neuropsychological impairments.

Table 3. Prevalence and number of subjects with cognitive impairment without dementia, using different definitions, by age class and gender

					Age	(years)			
Diagnosis		65-69		70-74		75-79		80-84		
	N.	%	N.	%	N.	%	N.	%	N.	%
Men										
AACD	31	7.1	39	9.5	46	11.2	40	12.9	156	10.0
AACD-3*	72	16.6	75	18.3	83	20.1	57	18.4	287	18.3
ND-N**	89	20.5	62	15.2	72	17.5	41	13.3	264	16.9
SCC-NI***	9	2.1	5	1.2	10	2.4	5	1.6	29	1.9
Women										
AACD	23	5.7	29	8.0	38	10.3	28	9.9	118	8.3
AACD-3*	58	14.4	70	19.2	87	23.6	59	20.8	274	19.3
ND-N**	80	19.9	65	17.9	54	14.6	45	15.8	244	17.2
SCC-NI***	3	0.7	5	1.4	5	1.4	2	0.7	15	1.1

^{*}Individuals with cognitive impairment without dementia fulfilling only 3 of the 5 AACD criteria.

^{**}Individuals with documented neuropsychological deficits but otherwise with normal cognitive function.

^{***}Individuals with subjective cognitive complaints without neuropsychological impairments.

Table 3. Prevalence and number of subjects with cognitive impairment without dementia, using different definitions, by age class and gender

					Age	(years)			
Diagnosis	65	65-69		70-74		75-79		80-84		
	N.	%	N.	%	N.	%	N.	%	N.	%
Men										
AACD	31	7.1	39	9.5	46	11.2	40	12.9	156	10.0
AACD-3*	72	16.6	75	18.3	83	20.1	57	18.4	287	18.3
ND-N**	89	20.5	62	15.2	72	17.5	41	13.3	264	16.9
SCC-NI***	9	2.1	5	1.2	10	2.4	5	1.6	29	1.9
Women										
AACD	23	5.7	29	8.0	38	10.3	28	9.9	118	8.3
AACD-3*	58	14.4	70	19.2	87	23.6	59	20.8	274	19.3
ND-N**	80	19.9	65	17.9	54	14.6	45	15.8	244	17.2
SCC-NI***	3	0.7	5	1.4	5	1.4	2	0.7	15	1.1

^{*}Individuals with cognitive impairment without dementia fulfilling only 3 of the 5 AACD criteria.

^{**}Individuals with documented neuropsychological deficits but otherwise with normal cognitive function.

^{***}Individuals with subjective cognitive complaints without neuropsychological impairments.

Table 3. Prevalence and number of subjects with cognitive impairment without dementia, using different definitions, by age class and gender

					Age	(years	<u>,</u>)			
Diagnosis		5-69	70	70-74		75-79		80-84		
	N.	%	N.	%	N.	%	N.	%	N.	%
Men										
AACD	31	7.1	39	9.5	46	11.2	40	12.9	156	10.0
AACD-3*	72	16.6	75	18.3	83	20.1	57	18.4	287	18.3
ND-N**	89	20.5	62	15.2	72	17.5	41	13.3	264	16.9
SCC-NI***	9	2.1	5	1.2	10	2.4	5	1.6	29	1.9
Women										
AACD	23	5.7	29	8.0	38	10.3	28	9.9	118	8.3
AACD-3*	58	14.4	70	19.2	87	23.6	59	20.8	274	19.3
ND-N**	80	19.9	65	17.9	54	14.6	45	15.8	244	17.2
SCC-NI***	3	0.7	5	1.4	5	1.4	2	0.7	15	1.1

^{*}Individuals with cognitive impairment without dementia fulfilling only 3 of the 5 AACD criteria.

^{**}Individuals with documented neuropsychological deficits but otherwise with normal cognitive function.

^{***}Individuals with subjective cognitive complaints without neuropsychological impairments.

Table 3. Prevalence and number of subjects with cognitive impairment without dementia, using different definitions, by age class and gender

					Age	(years)			
Diagnosis	65	65-69		70-74		75-79		80-84		
	N.	%	N.	%	N.	%	N.	%	N.	%
Men										
AACD	31	7.1	39	9.5	46	11.2	40	12.9	156	10.0
AACD-3*	72	16.6	75	18.3	83	20.1	57	18.4	287	18.3
ND-N**	89	20.5	62	15.2	72	17.5	41	13.3	264	16.9
SCC-NI***	9	2.1	5	1.2	10	2.4	5	1.6	29	1.9
Women										
AACD	23	5.7	29	8.0	38	10.3	28	9.9	118	8.3
AACD-3*					87		59	20.8	274	19.3
	58	14.4		19.2		23.6				
ND-N**	80	19.9	65	17.9	54	14.6	45	15.8	244	17.2
SCC-NI***	3	0.7	5	1.4	5	1.4	2	0.7	15	1.1

^{*}Individuals with cognitive impairment without dementia fulfilling only 3 of the 5 AACD criteria.

^{**}Individuals with documented neuropsychological deficits but otherwise with normal cognitive function.

^{***}Individuals with subjective cognitive complaints without neuropsychological impairments.


Le previsioni epidemiologiche Età – Deficit Cognitivo


 Ad oggi si stima che 1 ultra-65 enne su 3 ha disturbi della sfera cognitiva.

 L'aumento della quota di ultra-85enni potrebbe modificare questo rapporto ad 1:2 visto l'aumento di questa fascia di popolazione.

Young and Elderly Italian Population (milions) 1950-2020








modified by ONU, 1993


Characteristics of distribution of cognitive function among subjects aged 55 to 94 years according to age.

THE ROTTERDAM STUDY




Breteler MMB et al. BMJ 1994

Malattia di Alzheimer: modifica dei pattern epidemiologici nei paesi Europei 2000-2040




Lancet 2005

Epidemiologia




2001 Total in all WHO regions: 24.3 million




^{* &}amp; Developing Western Pacific Region. From Ferri et al, Lancet 2005;366:2112–2117.

Epidemiologia




2020 Predicted total in all WHO regions: 42.3 million




^{* &}amp; Developing Western Pacific Region. From Ferri et al, Lancet 2005;366:2112-2117.

Epidemiologia



2040 Predicted total in all WHO regions: 31.1 million



^{* &}amp; Developing Western Pacific Region. From Ferri et al, Lancet 2005;366:2112-2117.

Incidenza della demenza

ILSA - CNR [Italian Longitudinal Study on Aging]

Età	Maschi	Femmine	Totale		
65-69	4,1	3,8	4,0		
70-74	5,8	9,9	7,7		
75-79	13,7	21,6	17,4		
80-84	32,1	27,3	29,9		
Totale	10,3	13,3	11,9		
			(9,9-13,9)		

Questi dati di incidenza comportano una stima di circa 96.000 nuovi casi di demenza ogni anno nella popolazione anziana italiana.


Comorbidity of 10 common conditions

Percentage of patients Painful Condition Aria librilation with the row condition Heartailire Percentage Mean No of Mean No of who also have the Diabete's who only conditions in conditions in column condition have the row people aged people aged condition* <65 years with ≥65 years with row condition row condition Coronary heart disease 8.8 3.4 4.4 3.6 Hypertension 21.9 2.5 0 5.6 Heart failure 0 2.8 3.9 Stroke/transient ischaemic attack 6.0 3.6 4.8 6.5 3.3 5.0 Atrial fibrillation 17.6 2.9 6.5 Diabetes 0 Chronic obstructive pulmonary disease 2.8 4.5 14.3 12.7 3.1 4.3 Painful condition 6 0 0 25.4 2.6 4.9 Depression 0 5.3 4.1 Dementia 4.6




^{*} Percentage who do not have one of 39 other conditions in the full count

Pharmacological treatment of AD



Stone JG, Casadesus G, Gustaw-Rothenberg K, et al. Frontiers in Alzheimer's disease therapeutics. Ther Adv Chronic Dis 2011; 2 (1): 9-23

Drug development in AD



Mangialasche F Lancet Neurol 2010; 9: 702-16

The Diagnosis and Management of Mild Cognitive Impairment A Clinical Review

		Patients				
Source	No.	Characteristics	Mean Age, y	Intervention	Trial Length	Primary Outcomes
Pharmacologic Trea	tments	a o				
Salloway et al, ⁴² 2004	270	Adults with MCI	72	Donepezil, 10 mg/d vs placebo	24 wk	No significant differences between treatment groups in the 2 primary outcomes: New York University Paragraph Delayed Recall test and the ADCS-CGIC-MCI. ^b
Petersen et al, 2005 ⁴³	769	Adults with amnestic MCI	73	Donepezil, 10 mg/d vs 2000 IU/d of vitamin E vs placebo	3 y	Compared with placebo, there were no significant differences in the probability of progression to Alzheimer disease in the vitamin E group (HR, 1.02 ; 95% CI, $0.74-1.41$; $P = .91$) or the donepezil group (HR, 0.80 ; 95% CI, $0.57-1.13$; $P = .42$).
Doody et al, ⁴⁴ 2009	821	Adults with amnestic MCI	70	Donepezil, 10 mg/d vs placebo	48 wk	The dual primary efficacy end point was not reached. At 48 weeks, there was a small, significant decrease in modified ADAS-cog ^b (-0.90 [SE, 0.37]) favoring donepezil ($P = .01$). Changes in CDR-SB scores ^b were minimal and not significantly different between treatment groups.
Koontz and Baskys, ⁴⁵ 2005	19	Men with MCI	71	Galantamine, 12 mg twice daily vs placebo	16 wk	The primary outcome was the CANTAB. ^b At 16 weeks, only 1 of the 6 subtests of the CANTAB (stockings of Cambridge test) ^b differed significantly between galantamine and placebo groups (mean [SD], 8.3 [1.9] vs 7.0 [1.4]; <i>P</i> = .02).

No medications have proven effective for MCI; treatments and interventions should be aimed at reducing cardiovascular risk factors and prevention of stroke. Aerobic exercise, mental activity, and social engagement may help decrease risk of cognitive decline.

Langa KM JAMA 312: 2551-2561, 2014

Indirect pathways





Fig. 1. Examples of direct and indirect associations between environment and cognition.

^{*} Cardiovascular.

Risk factors for dementia and Alzheimer's disease across the lifespan




Sindi et al. F1000Prime Rep. 2015;7:50.

CLINICAL REVIEW


Guidelines for the Management of Cognitive and Behavioral Problems in Dementia

Carl H. Sadowsky, MD, and James E. Galvin, MD, MPH



J Am Board Fam Med 2012; 25:350-366

Therapeutic options for AD



Brian Training and Cognitive Impairment

Brain Test Britain


the largest ever study into computer-based brain training

Brain Test Britain – partecipants

- * 67,186 people (7 Sept to 25 November 2009)
- * 57.6% of Brain Test Britain participants were women
- Participants had generally reached a high level of education,
 The average age of people signing up to take part was 43
- Older trainers were more likely to complete more training sessions than younger trainers

Reasoning brain training





Non-reasoning brain training






Brain Test Britain is the largest ever study into computer-based brain training







Journal of Applied Gerontology 2015, Vol. 34(3) NP166–NP189 © The Author(s) 2013 Reprints and permissions: sagepub.com/journalsPermissions.nav DOI: 10.1177/0733464812470747 jag.sagepub.com



Abstract

This systematic review examined the physical and cognitive effects of physically based interactive computer games (ICGs) in older adults. Literature searching was carried out from January 2000 to June 2011. Eligible studies were trials involving older adults (>65 years) describing the effects of ICGs with a physical component (aerobic, strength, balance, flexibility) on physical or cognitive outcomes. Secondary outcomes included adverse effects, compliance, and enjoyment. Twelve trials met the inclusion criteria. ICG interventions varied in terms of software, game type, and nature of the computer interaction. Although there was preliminary evidence that ICG is a safe and effective exercise intervention for older adults, the dearth of high-quality evidence limits this finding. No major adverse effects were reported and two studies reported minor events. ICG could be improved further by tailoring interventions for older adults; in particular, they should aim to optimize participant safety, motivation, and enjoyment for this population.

Cognitive activities and risk of cognitive decline

Study	Sample (n)	Followup	Exposure	Case definition	Confounding adjustment	Results
2009 ³³⁵	Clinical cohort – HMO (626)	14 years	Self-report on the socializing, educational, and cultural items on the Life Complexity Inventory Proportion of time spent weekly in cognitive activities divided by time spent in all leisure activities	Longitudinal performance on: Measures of verbal memory: (a) Word fluency (b) Immediate recall (c) Delayed recall Measures of inductive reasoning: (a) PMA reasoning measure (b) ADEPT Letter Series test (c) Word series and (d) Educational Testing Service number series	Age Sex Educational level Income	Involvement in cognitive leisure activities was not associated with longitudinal performance on either the memory or inductive reasoning tasks. Specific results were not provided in the manuscript.

Abbreviations: ADEPT = Adult Development and Enrichment Project; aMCI = amnestic mild cognitive impairment; CI = confidence interval; HMO = health maintenance organization; HR = hazard ratio; MCI = mild cognitive impairment; MMSE = Mini-Mental State Examination; PMA = Primary Mental Abilities; SD = standard deviation; SE = standard error

Recommendations for Future Trials Investigating the Effectiveness of Interactive Computer Games (ICGs)

Selection/inclusion criteria

Methodology

ICG intervention

Comparison group

Outcomes and follow-up

- Elderly adults with particular focus on participants aged > 80 years
- Randomized controlled design (predetermined randomization schedule and allocation concealment)
- Blinded outcome assessment
- Minimize attrition bias through active tracking of dropouts/ intention to treat analysis
- Game design or accessories developed to challenge a specific component of fitness, for example, strengthening or falls prevention
- User-friendly software tailored to elderly population
- Maximize enjoyment, engagement, and motivation during exercise by ensuring ICG themes correspond to the interests of the elderly population
- Maximize programmable game features, for example, incorporating baseline calibration to tailor game features to individuals' ability/fitness levels
- Nongame exercise
- Optimal exercise dose (duration intensity)
- Subgroup effects (gender, baseline physical, or cognitive ability)
- Active control group recognized as a necessity for cognitive intervention studies
- Physical and cognitive-based outcomes
- Mechanistic and clinically relevant
- Active follow-up of predefined adverse events

Bleakley et al J Appl Gerontolo 2015; 34(3)

Recommendations for Future Trials Investigating the Effectiveness of Interactive Computer Games (ICGs)

Selection/inclusion criteria

Methodology

ICG intervention

Comparison group

Outcomes and follow-up

- Elderly adults with particular focus on participants aged > 80 years
- Randomized controlled design (predetermined randomization schedule and allocation concealment)
- Blinded outcome assessment
- Minimize attrition bias through active tracking of dropouts/ intention to treat analysis
- Game design or accessories developed to challenge a specific component of fitness, for example, strengthening or falls prevention
- User-friendly software tailored to elderly population
- Maximize enjoyment, engagement, and motivation during exercise by ensuring ICG themes correspond to the interests of the elderly population
- Maximize programmable game features, for example, incorporating baseline calibration to tailor game features to individuals' ability/fitness levels
- Nongame exercise
- Optimal exercise dose (duration intensity)
- Subgroup effects (gender, baseline physical, or cognitive ability)
- Active control group recognized as a necessity for cognitive intervention studies
- Physical and cognitive-based outcomes
- Mechanistic and clinically relevant
- Active follow-up of predefined adverse events

Bleakley et al J Appl Gerontolo 2015; 34(3)



Physical activity level and future risk of mild cognitive impairment or dementia: a critically appraised topic.

Objective measurement confirms that greater levels of physical activity are associated with decreased risk of a future diagnosis of MCI or AD. Further studies are needed to confirm the temporal association of exercise and future cognitive health and understand the relevant underlying biological mechanisms.

Schlosser Covell GE Neurologist 19: 89-91, 2015

Original Article

Journal of INTERNAL MEDICINE

doi: 10.1111/j.1365-2796.2010.02281.x

Physical activity and risk of cognitive decline: a meta-analysis of prospective studies

• F. Sofi^{1,2,3}, D. Valecchi¹, D. Bacci¹, R. Abbate², G. F. Gensini¹, A. Casini³ & C. Macchi¹

From the ¹Don Carlo Gnocchi Foundation, Centro S. Maria agli Ulivi, Onlus IRCCS; ²Department of Medical and Surgical Critical Care, Thrombosis Centre, University of Florence; and ³Regional Agency of Nutrition, Azienda Ospedaliero-Universitaria Careggi, Florence, Italy

J Intern Med 2011; **269**: 107–117.

Forest plot of studies investigating a low-to-moderate level of physical activity

		Risk ratio	Risk ratio
Study or Subgroup	Weight	IV, Random, 95% CI	IV, Random, 95% CI
Ho et al., (M)	3.0%	0.53 [0.25, 1.12]	
Ho <i>et al.,</i> (F)	5.9%	0.53 [0.32, 0.87]	
Laurin <i>et al.,</i> (M)	6.4%	0.84 [0.53, 1.34]	
Laurin et al., (F)	7.6%	0.55 [0.36, 0.83]	
Schuit et al.,	1.5%	0.56 [0.19, 1.66]	
Yaffe et al.,	16.0%	0.78 [0.64, 0.96]	
Pignatti <i>et al.,</i>	1.4%	0.27 [0.09, 0.82]	
Lytle <i>et al.,</i>	6.4%	0.63 [0.40, 1.00]	
Flicker et al.,	3.4%	0.50 [0.25, 1.00]	
Singh-Manoux et al.,	14.8%	0.81 [0.65, 1.01]	
Sumic et al., (M)	1.1%	0.91 [0.25, 3.36]	
Sumic et al., (F)	1.1%	0.12 [0.03, 0.44]	
Middleton et al.,	15.2%	0.73 [0.59, 0.91]	
Niti et al.,	12.1%	0.60 [0.45, 0.80]	
Etgen <i>et al.,</i>	4.1%	0.44 [0.24, 0.82]	
Total (95% CI)	100.0%	0.65 [0.57, 0.75]	
Heterogeneity: Tau ² =	0.02; $\chi^2 =$	= 20.93, df = 14 (P = 0.10); I ² = 33%	0.05 0.2 1 5 20
Test for overall effect:	Z = 6.17 (P < 0.00001)	0.05 0.2 1 5 20 No cognitive decline Cognitive decline

Sofi et al. J Intern Med 2011; 269: 107-117

Association of physical activity and different components of healthy ageing over 8 years follow-up

	Model 1 OR (95% CI)	Model 2 OR (95% CI)
Chronic disease		
Inactive	1.00 (ref)	1.00
Moderate physical activity	0.70 (0.58 to 0.84)	0.78 (0.64 to 0.95
Vigorous physical activity	0.61 (0.50 to 0.74)	0.67 (0.54 to 0.84
p-trend	<0.001	0.001
Depressive symptoms (CES-D>3)		
Inactive	1.00 (ref)	1.00
Moderate physical activity	0.51 (0.41 to 0.64)	0.67 (0.53 to 0.85
Vigorous physical activity	0.36 (0.27 to 0.46)	0.51 (0.39 to 0.67
p-trend	<0.001	0.001
Cognitive impairment		
Inactive	1.00 (ref)	1.00
Moderate physical activity	0.71 (0.56 to 0.90)	0.88 (0.69 to 1.13
Vigorous physical activity	0.49 (0.37 to 0.64)	0.64 (0.48 to 0.85
p-trend	<0.001	0.005
ADL/IADL		
Inactive	1.00 (ref)	1.00
Moderate physical activity	0.43 (0.35 to 0.52)	0.57 (0.46 to 0.70
Vigorous physical activity	0.30 (0.24 to 0.37)	0.41 (0.33 to 0.52
p-trend	<0.001	<0.001
Impaired gait speed (<0.6 m/s)		
Inactive	1.00 (ref)	1.00
Moderate physical activity	0.38 (0.30 to 0.49)	0.54 (0.40 to 0.72
Vigorous physical activity	0.23 (0.17 to 0.32)	0.41 (0.29 to 0.58
p-trend	<0.001	<0.001

Model 2; adjustment for age, sex and mutually for all components of healthy ageing model.

ADL, activities of daily living; CES-D, Centre of Epidemiological Studies Depression; IADL, instrumental activities of daily living.

Hamer M, et al. Br J Sports Med 2014;48:239–243


Association of physical activity and different components of healthy ageing over 8 years followup

	Model 1 OR (95% CI)	Model 2 OR (95% CI)
Chronic disease		
Inactive	1.00 (ref)	1.00
Moderate physical activity	0.70 (0.58 to 0.84)	0.78 (0.64 to 0.95
Vigorous physical activity	0.61 (0.50 to 0.74)	0.67 (0.54 to 0.84
p-trend	<0.001	0.001
Depressive symptoms (CES-D>3)		
Inactive	1.00 (ref)	1.00
Moderate physical activity	0.51 (0.41 to 0.64)	0.67 (0.53 to 0.85
Vigorous physical activity	0.36 (0.27 to 0.46)	0.51 (0.39 to 0.67)
p-trend	<0.001	0.001
Cognitive impairment		
Inactive	1.00 (ref)	1.00
Moderate physical activity	0.71 (0.56 to 0.90)	0.88 (0.69 to 1.13
Vigorous physical activity	0.49 (0.37 to 0.64)	0.64 (0.48 to 0.85
p-trend	<0.001	0.005
ADL/IADL		
Inactive	1.00 (ref)	1.00
Moderate physical activity	0.43 (0.35 to 0.52)	0.57 (0.46 to 0.70
Vigorous physical activity	0.30 (0.24 to 0.37)	0.41 (0.33 to 0.52
p-trend	<0.001	<0.001
Impaired gait speed (<0.6 m/s)		
Inactive	1.00 (ref)	1.00
Moderate physical activity	0.38 (0.30 to 0.49)	0.54 (0.40 to 0.72)
Vigorous physical activity	0.23 (0.17 to 0.32)	0.41 (0.29 to 0.58
p-trend	<0.001	<0.001


Hamer M, et al. Br J Sports Med 2014;48:239–243


model.

ADL, activities of daily living; CES-D, Centre of Epidemiological Studies Depression; IADL, instrumental activities of daily living.



Hyodo et al. Neurobiology of Aging 2012;33:2621-32







Available online at www.sciencedirect.com



Experimental Gerontology 41 (2006) 764-770

Experimental Gerontology

www.elsevier.com/locate/expgero

Exercise training affects age-induced changes in SOD and heat shock protein expression in rat heart

Barbara Rinaldi ^{a,*,1}, Graziamaria Corbi ^{b,*,1}, Silvia Boccuti ^a, Walter Filippelli ^c, Giuseppe Rengo ^b, Dario Leosco ^d, Francesco Rossi ^a, Amelia Filippelli ^a, Nicola Ferrara ^b

Department of Experimental Medicine and Excellence Center of Cardiovascular Disease, Second University of Naples, Naples 80138, Italy
 Department of Health Sciences, University of Molise and S. Maugeri Foundation, Scientific Institute of Telese Terme, Telese Terme 82037, Italy
 Faculty of Sport and Exercise Sciences, Parthenope University, Naples, Italy

Department of Clinical Medicine and Cardiovascular and Immunological Sciences, University "Federico II", Naples, Italy


Received 13 January 2006; received in revised form 26 March 2006; accepted 16 May 2006 Available online 5 July 2006 REJUVENATION RESEARCH Volume 10, Number 4, 2007 © Mary Ann Liebert, Inc. DOI: 10.1089/rej.2007.0576

Exercise Training Promotes SIRT1 Activity in Aged Rats

Nicola Ferrara,^{1,2*} Barbara Rinaldi,^{3*} Graziamaria, Corbi,^{1,2} Valeria Conti,³ Paola Stiuso,⁴ Silvia Boccuti,³ Giuseppe Rengo,² Francesco Rossi,³ and Amelia Filippelli ³

Exercise Training Promotes SIRT1 Activity in Aged Rats

Nicola Ferrara, 1,2* Barbara Rinaldi, 3* Graziamaria, Corbi, 1,2 Valeria Conti, 3 Paola Stiuso, 4 Silvia Boccuti,3 Giuseppe Rengo,2 Francesco Rossi,3 and Amelia Filippelli 3



TO

Rejuvenation Res. 2008 Feb;11(1):139-50.

Exercise training promotes SIRT1 activity in aged rats.

Ferrara N, Rinaldi B, Corbi G, Conti V, Stiuso P, Boccuti S, Rengo G, Rossi F, Filippelli A.

Med Sci Sports Exerc. 2012 Jan;44(1):39-49. doi: 10.1249/MSS.0b013e318227f69c.

Oxidative stress effects on endothelial cells treated with different athletes' sera.

Conti V, Corbi G, Russomanno G, Simeon V, Ferrara N, Filippelli W, Limongelli F, Canonico R, Grasso C, Stiuso P, Dicitore A, Filippelli A.

Med Sci Sports Exerc. 2013 Apr;45(4):644-53. doi: 10.1249/MSS.0b013e318279fb59.

Aerobic training workload affects human endothelial cells redox homeostasis.

Conti V, Russomanno G, Corbi G, Guerra G, Grasso C, Elippelli W, Paribello V, Ferrara N, Filippelli A.

Aging Clin Exp Res. 2015 Aug;27(4):547-53. doi: 10.1007/s40520-015-0357-9. Epub 2015 Apr 3.

Aging-related changes in oxidative stress response of human endothelial cells.

Conti V¹, Corbi G, Simeon V, Russomanno G, Manzo V, Ferrara N, Filippelli A.

EXERCISE IN THE PREVENTION OF DEMENTIA (EPD)


- ♦ >60 anni
- disturbo soggettivo della memoria
- ⇒ >/=24 MMSE

STUDIO EPD






GRUPPO SPERIMENTALE




GRUPPO CONTROLLO




FOLLOW UP A 6 - 12 - 24 MESI

STUDIO EP RECLUTAMENTO DEL CAMPIONE




Valutare se l'attività delle sirtuine condizionasse la risposta cognitiva all'esercizio


ANALISI DI BEGBESSIONE LINEABE



ANALISI DI BEGRESSIONE LINEARE



ANALISI DI BEGBESSIONE LINEABE




Finnish Geriatric Intervention Study to Prevent Cognitive Impairment and Disability (FINGER)

Ngandu T Lancet 385: 2255-63, 2015


A 2 year multidomain intervention of diet, exercise, cognitive training, and vascular risk monitoring versus control to prevent cognitive decline in at-risk elderly people (FINGER): a randomised controlled trial

diet, exercise, cognitive training, vascular risk monitoring



Ngandu T Lancet 385: 2255-63, 2015

A 2 year multidomain intervention of diet, exercise, cognitive training, and vascular risk monitoring versus control to prevent cognitive decline in at-risk elderly people (FINGER): a randomised controlled trial



....a multidomain intervention could improve or maintain cognitive functioning in at-risk elderly people from the general population.

Ngandu T Lancet 385: 2255-63, 2015


Characteristics of selected RCTs for prevention of cognitive impairment, dementia and Alzheimer's disease based on multidomain interventions

RCT	FINGER	MAPT	PreDIVA
Sample size	1260 community dwellers, from previous population-based observational cohorts	1680 community dwellers	3533 community dwellers
Main inclusion criteria	CAIDE Dementia Risk Score >6 and cognition at mean level/slightly lower than expected for age (CERAD test battery)	Frail elderly people, subjective memory complaint, slow walking speed, limitation in IADL (MMSE>24)	All elderly within GP practices, non demented (MMSE >23)
Age at enrolment	60–77 yrs	≥70 yrs	70–78 yrs
Study design	Multi-center, randomized, parallel-group controlled trial	Multi-center, randomized, controlled trial	Multi-center, cluster-randomized, parallel group controlled trial
Intervention	Multi-domain: nutritional guidance, physical activity, cognitive training, increased social activity and intensive monitoring and management of metabolic and vascular risk factors	Multi-domain: vascular care, nutritional advice, exercise advice, cognitive training, and/or DHA 800 mg/day	Multi-domain: nurse-led vascular care including medical treatment of risk factors, nutritional advice, exercise advice
Duration	2 yrs + 5 yrs extended follow-up	3 yrs + 2 yrs extended follow-up	6 yrs
Outcomes	Primary: change in cognitive function (neuropsychological test battery, Trail Making, Stroop), Secondary: dementia, cardiovascular events, depression, disability, quality of life, health resources utilisation, AD biomarkers change	Primary: change in cognitive function (Grober and Buschke memory test) Secondary: cognition (MMSE, CDR), functional status, depression, health resources utilisation, AD biomarkers change	Primary: dementia, disability Secondary: cognitive decline (MMSE, VAT), depression, cardiovascular events
Status	Intervention was completed in March 2014	Intervention was completed in March 2014	Ongoing, will be completed in 2015

CDR, clinical dementia rating scale; DHA, docosahexaenoic acid; FINGER, Finnish Geriatric Intervention Study to Prevent Cognitive Impairment and Disability; GP, general practitioner; IADL, instrumental activities of daily living; MAPT, Multidomain Alzheimer Prevention Study; PreDIVA, Prevention of Dementia by Intensive Vascular Care; VAT, visual association test.

Sindi et al. F1000Prime Rep. 2015;7:50.

Efficacy of cognitive rehabilitation therapies for mild cognitive impairment (MCI) in older adults: Working toward a theoretical model and evidence-based interventions



Huckansa M Neuropsychol Rev. 23: 63-80, 2013

Int J Geriatr Psychiatry. 2010 Jan;25(1):30-6. doi: 10.1002/gps.2294.

Education, occupation and retirement age effects on the age of onset of Alzheimer's disease.

<u>Lupton MK¹, Stahl D, Archer N, Foy C, Poppe M, Lovestone S, Hollingworth P, Williams J, Owen MJ, Dowzell K, Abraham R, Sims R, Brayne C, Rubinsztein D, Gill M, Lawlor B, Lynch A, Powell JF.</u>

Author information

Abstract

OBJECTIVE: To determine the effects of early life education, mid life employment and later life retirement age on the age of onset (AOO) of Alzheimer's disease (AD).

METHODS: Multiple regression analyses were carried out using data for 1320 probable AD cases, of which 382 were males with employment and retirement age data, using informant based information on education and employment.

RESULTS: No relation was found between years of education, best qualification obtained, or employment variables in males and the AOO of AD. A significant effect of later retirement age in delaying the AOO of AD was seen in males.

CONCLUSIONS: In this study no effect of education or employment was seen, although this may be due to limited variance in the study population. The significant effect of retirement age may have several explanations, the most interesting of which would be the suggestion that active employment later in life allows an individual to prolong their cognitive assets above the threshold for dementia.

LAVORARE FINO A TARDI ALLONTANA IL RISCHIO DI ALZHEIMER

Ogni anno di lavoro in più ritarda di sei settimane l'inizio della vecchiaia

Mantenere il cervello attivo lavorando fino a tardi e' un modo efficace per tenere lontano e ritardare l'Alzheimer. A sostenerlo e' uno studio dell'istituto di psichiatrica del King's college di Londra, pubblicato sull'International Journal of Geriatric Psychiatry'. In particolare si stima che ogni anno in piu' di lavoro corrisponda a sei settimane di ritardo dell'inizio della vecchiaia. Alla conclusione i ricercatori vi sono giunti dopo aver analizzato i dati di 1.320 pazienti malati di demenza, di cui 382 uomini. Cosi' hanno scoperto che per gli uomini continuare a lavorare fino a tardi aiuta a mantenere il cervello abbastanza attivo e di ritardare la demenza, causata dalla perdita di cellule nel cervello. Secondo gli esperti un modo per accumulare il maggior numero possibile di connessioni cellulari e' quello di mantenersi mentalmente attivi nella vita. In questo senso una buona educazione intellettuale e scolastica puo' aiutare a mantenere la cosiddetta "riserva cognitiva" come anche la stimolazione intellettiva continuata in tarda eta'. Si e' visto infatti che le persone andate in pensionetardi hanno sviluppato l'Alzheimer successivamente rispetto a quelle che hanno lasciato il lavoro prima.



